As of this week in Montana, the state has moved ahead with new rules designed to position itself as an experimental medical hub, drawing attention from biotech firms and patient advocates alike. According to MIT Technology Review's daily newsletter, The Download, the rules lower the threshold for when investigational drugs can be offered, allowing biotech companies whose drugs have been through preliminary testing to advance them further.
The excerpt notes that this preliminary testing has in some cases involved as few as 10 participants. Supporters of such right-to-try expansions typically argue the change is essential for rare-disease communities with few remaining options, while critics warn that compressing the trial pipeline could expose patients to poorly understood risks.
The move is framed as part of Montana's broader plan to become an experimental medical hub. As other states weigh similar measures, Montana's approach may serve as a bellwether for how far jurisdictions are willing to go in creating state-level pathways for experimental therapies.